CorMedix (NASDAQ:CRMD – Get Free Report) and Helix BioPharma (OTCMKTS:HBPCF – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, profitability and institutional ownership.
Earnings & Valuation
This table compares CorMedix and Helix BioPharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CorMedix | $60,000.00 | 10,619.00 | -$46.34 million | ($0.81) | -12.96 |
| Helix BioPharma | N/A | N/A | -$6.82 million | ($0.10) | -4.55 |
Helix BioPharma has lower revenue, but higher earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Analyst Recommendations
This is a summary of recent ratings and target prices for CorMedix and Helix BioPharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CorMedix | 0 | 0 | 6 | 0 | 3.00 |
| Helix BioPharma | 0 | 0 | 0 | 0 | 0.00 |
CorMedix currently has a consensus target price of $15.67, suggesting a potential upside of 49.21%. Given CorMedix’s stronger consensus rating and higher possible upside, equities research analysts plainly believe CorMedix is more favorable than Helix BioPharma.
Profitability
This table compares CorMedix and Helix BioPharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CorMedix | N/A | -79.21% | -64.68% |
| Helix BioPharma | N/A | N/A | -1,097.76% |
Institutional and Insider Ownership
34.2% of CorMedix shares are held by institutional investors. 5.2% of CorMedix shares are held by company insiders. Comparatively, 7.6% of Helix BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
CorMedix beats Helix BioPharma on 7 of the 12 factors compared between the two stocks.
About CorMedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
About Helix BioPharma
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
